Education
About Us
Working with TipRanks
Follow Us
Abbott Laboratories (ABT)
NYSE:ABT
ABT Stock Chart & Stats
$125.45
-$0.27(-0.24%)
At close: 4:00 PM EST
$125.45
-$0.27(-0.24%)
Day’s Range― - ―
52-Week Range$110.86 - $141.23
Previous CloseN/A
Volume1.03M
Average Volume (3M)6.22M
Market Cap
$218.14B
Enterprise Value$239.83B
Total Cash (Recent Filing)$7.73B
Total Debt (Recent Filing)$12.94B
Price to Earnings (P/E)15.7
Beta0.27
Next Earnings
Jan 28, 2026EPS Estimate
1.5Next Dividend Ex-DateN/A
Dividend Yield1.88%
Share Statistics
EPS (TTM)1.30
Shares Outstanding1,738,872,000
10 Day Avg. Volume5,961,044
30 Day Avg. Volume6,224,125
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)4.11
Price to Sales (P/S)4.67
P/FCF Ratio30.84
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue5.47
Enterprise Value/Gross Profit10.13
Enterprise Value/Ebitda20.46
Forecast
1Y Price Target
$147.53Price Target Upside17.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)5.15
Revenue Forecast (FY)$44.67B
Bulls Say, Bears Say
Bulls Say
Diagnostics Market LeadershipThe acquisition positions Abbott as a leader in the $60B U.S. cancer screening and precision oncology diagnostics market, increasing its annual sales to over $12B.
International ExpansionThere are opportunities to introduce the Exact product portfolio to international customers by leveraging Abbott’s established infrastructure.
Revenue GrowthThe acquisition of Exact Sciences will provide an immediate boost to revenue growth with its domestically-focused revenue.
Bears Say
Competitive PressuresThe competitive landscape for Exact Sciences' flagship product, Cologuard, has become more complicated following the approval of Guardant's Shield test.
EPS DilutionThe acquisition would reduce Adjusted EPS by $0.20 in 2026 and $0.16 in 2027, with expected recovery thereafter.
Lack Of Additional SynergiesThere is a lack of additional synergies, with the expected $100 million in annual pre-tax synergies by 2028 being considered a floor.
Abbott Laboratories News
ABT FAQ
What was Abbott Laboratories’s price range in the past 12 months?
Abbott Laboratories lowest stock price was $110.86 and its highest was $141.23 in the past 12 months.
What is Abbott Laboratories’s market cap?
Abbott Laboratories’s market cap is $218.14B.
When is Abbott Laboratories’s upcoming earnings report date?
Abbott Laboratories’s upcoming earnings report date is Jan 28, 2026 which is in 39 days.
How were Abbott Laboratories’s earnings last quarter?
Abbott Laboratories released its earnings results on Oct 15, 2025. The company reported $1.3 earnings per share for the quarter, missing the consensus estimate of $1.303 by -$0.003.
Is Abbott Laboratories overvalued?
According to Wall Street analysts Abbott Laboratories’s price is currently Undervalued.
Does Abbott Laboratories pay dividends?
Abbott Laboratories pays a Quarterly dividend of $0.59 which represents an annual dividend yield of 1.88%. See more information on Abbott Laboratories dividends here
What is Abbott Laboratories’s EPS estimate?
Abbott Laboratories’s EPS estimate is 1.5.
How many shares outstanding does Abbott Laboratories have?
Abbott Laboratories has 1,738,872,000 shares outstanding.
What happened to Abbott Laboratories’s price movement after its last earnings report?
Abbott Laboratories reported an EPS of $1.3 in its last earnings report, missing expectations of $1.303. Following the earnings report the stock price went down -2.434%.
Which hedge fund is a major shareholder of Abbott Laboratories?
Currently, no hedge funds are holding shares in ABT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abbott Laboratories Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$147.53 (17.60% Upside)
$147.53 (17.60% Upside)
Blogger Sentiment
Bullish
ABT Sentiment 94%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 420.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $203.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
13.90%
12-Months-Change
Fundamentals
Return on Equity
30.62%
Trailing 12-Months
Asset Growth
13.21%
Trailing 12-Months
Company Description
Abbott Laboratories
Abbott Laboratories (ABT) is a global healthcare company that operates in various sectors, including diagnostics, medical devices, nutrition, and pharmaceuticals. Founded in 1888, Abbott is dedicated to advancing human health through the development of innovative products that address the needs of patients and healthcare providers. The company’s core products include diagnostic tests and systems, cardiac devices, diabetes care products, nutritional supplements, and branded pharmaceuticals.
ABT Company Deck
ABT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive performance with strong growth in most segments, particularly in medical devices and international markets. However, challenges remain, particularly in the diagnostics market in China and impacts from tariffs.View all ABT earnings summariesABT Net sales Breakdown
12.38% Established Pharmaceutical Products
20.05% Nutritional Products
22.27% Diagnostic Products
45.26% Medical Devices
0.04% Other
ABT Stock 12 Month Forecast
Average Price Target
$147.53
▲(17.60% Upside)
Technical Analysis
Ownership Overview
0.47% Insiders
25.00% Mutual Funds
20.79% Other Institutional Investors
32.55% Public Companies and Individual Investors